The stock of Affimed NV (NASDAQ:AFMD) hit a new 52-week low and has $1.94 target or 14.00% below today’s $2.25 share price. The 8 months bearish chart indicates high risk for the $71.79 million company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $1.94 price target is reached, the company will be worth $10.05M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 23,605 shares traded hands. Affimed NV (NASDAQ:AFMD) has declined 42.08% since March 14, 2016 and is downtrending. It has underperformed by 47.69% the S&P500.
Analysts await Affimed NV (NASDAQ:AFMD) to report earnings on November, 8. They expect $-0.25 earnings per share, up 7.41% or $0.02 from last year’s $-0.27 per share. After $-0.27 actual earnings per share reported by Affimed NV for the previous quarter, Wall Street now forecasts -7.41% EPS growth.
Affimed NV (NASDAQ:AFMD) Ratings Coverage
Out of 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. $19 is the highest target while $4 is the lowest. The $10.60 average target is 371.11% above today’s ($2.25) stock price. Affimed Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Jefferies initiated it with “Hold” rating and $11 target price in Wednesday, September 9 report. On Thursday, December 10 the stock rating was initiated by Laidlaw with “Buy”. Zacks upgraded the stock to “Hold” rating in Thursday, September 3 report. BMO Capital Markets initiated it with “Outperform” rating and $7 target price in Tuesday, April 12 report. On Friday, August 12 the stock rating was downgraded by Leerink Swann to “Market Perform”. Zacks upgraded Affimed NV (NASDAQ:AFMD) on Monday, August 10 to “Sell” rating. The stock of Affimed NV (NASDAQ:AFMD) earned “Hold” rating by Jefferies on Thursday, May 19. Wells Fargo initiated Affimed NV (NASDAQ:AFMD) on Friday, December 4 with “Outperform” rating. The firm has “Market Perform” rating by Leerink Swann given on Thursday, May 19. On Thursday, August 6 the stock rating was maintained by Oppenheimer with “Outperform”.
According to Zacks Investment Research, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.”
More recent Affimed NV (NASDAQ:AFMD) news were published by: Quotes.Wsj.com which released: “Affimed NV AFMD (US: Nasdaq)” on September 05, 2014. Also Zacks.com published the news titled: “Should You Get Rid of Affimed N.V. (AFMD) Now?” on August 14, 2015. Globenewswire.com‘s news article titled: “Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination …” with publication date: January 25, 2016 was also an interesting one.
AFMD Company Profile
Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Firm generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). The Company’s bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.